Tirosint Cost in Delaware 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is Tirosint and Why Does It Cost More Than Generic Levothyroxine Tablets?

Tirosint is a brand-name levothyroxine sodium gel capsule manufactured by IBSA Institut Biochimique. Each capsule contains only four ingredients: levothyroxine sodium, gelatin, glycerin, and water. The formulation eliminates the acacia, lactose, calcium sulfate dihydrate, and synthetic dyes found in most tablet forms. That simplified ingredient list matters clinically for a subset of patients.

Generic levothyroxine tablets at major Delaware pharmacy chains (CVS, Walgreens, Rite Aid, Giant Food pharmacies) typically cost $10, $25 per month for a 30-day supply at standard doses. Tirosint's ~$230 cash price reflects both the proprietary gel-cap manufacturing process and the brand exclusivity IBSA maintains. The FDA approved Tirosint in January 2013 for the treatment of hypothyroidism and as a pituitary TSH suppressant [1].

The higher price is clinically justified only for specific patient profiles. A 2014 study by Vita et al. published in Endocrine (N=42, crossover design) found that levothyroxine soft gel capsules produced significantly higher free T4 and free T3 concentrations than standard tablets in patients taking the drug with coffee, a common real-world interference factor [2]. Absorption differences in malabsorption syndromes are even more pronounced.

Patients with celiac disease, bariatric surgery history, atrophic gastritis, or lactose intolerance may absorb levothyroxine gel capsules substantially better than tablets. The FDA thyroid drug guidance document notes that even small changes in levothyroxine bioavailability can shift TSH outside the therapeutic window [1]. For those patients, a $230 monthly cost may prevent repeated lab draws, dose adjustments, and downstream cardiovascular risk from undertreated hypothyroidism.

Subclinical hypothyroidism affects roughly 4.3% of the U.S. population based on NHANES data [3], and overt hypothyroidism requires lifelong replacement therapy, making the monthly cost calculation genuinely consequential.

Tirosint Cash Price at Delaware Pharmacies in 2026

The average cash-pay price across Delaware retail pharmacies in 2026 is approximately $230 per month for a 30-day supply of Tirosint gel capsules. Prices vary modestly by location and dose strength.

Delaware has four main pharmacy markets: Wilmington, Dover, Newark, and Rehoboth Beach. Independent pharmacies in Wilmington's Trolley Square neighborhood and the Dover area sometimes negotiate lower acquisition costs than the big chains, but the spread is typically under $15. GoodRx and similar discount platforms list Delaware cash prices ranging from roughly $210 to $245 depending on the specific dose strength (13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, or 200 mcg). Higher doses do not always cost more; pricing is often flat across strength tiers for a given quantity.

Tirosint-SOL, the liquid formulation in unit-dose ampules, carries a similar or slightly higher price point than the gel capsules and is stocked at fewer Delaware pharmacies. Patients requiring the liquid form may need to call ahead or use a specialty pharmacy.

For uninsured Delaware residents, the most direct paths to cost reduction are the IBSA savings card (discussed below), GoodRx or RxSaver discount codes, and the 90-day supply option, which some pharmacies offer at a per-dose discount of 5 to 10% compared to monthly fills.

Does Delaware Medicaid Cover Tirosint?

Delaware Medicaid covers Tirosint with a prior authorization requirement for patients with documented hypothyroidism complicated by malabsorption or demonstrated intolerance to standard tablet formulations. Coverage is not automatic, and prescribers must submit a PA request through Delaware's DMAP (Division of Medicaid and Medical Assistance) portal.

The PA criteria typically require documentation of one or more of the following: (a) documented celiac disease or inflammatory bowel disease affecting levothyroxine absorption; (b) history of bariatric surgery such as Roux-en-Y gastric bypass; (c) persistent TSH elevation despite adequate doses of generic levothyroxine tablet; or (d) documented allergy or intolerance to tablet excipients such as lactose or acacia.

Delaware's Medicaid preferred drug list (PDL) lists generic levothyroxine tablets as the preferred thyroid hormone replacement agent. Brand-name Tirosint requires step therapy documentation in most cases. The American Thyroid Association's 2014 guidelines on hypothyroidism management state: "Levothyroxine is the standard of care for hypothyroidism, and brand or generic preparations should be used consistently to avoid fluctuations in thyroid hormone levels" [4]. That consistency principle is part of why Medicaid programs accept Tirosint when generic substitution is clinically problematic.

Managed Medicaid plans in Delaware, including those administered through Highmark Delaware and Molina Healthcare of Delaware, each maintain their own PDLs and PA forms. A prior authorization approved under DMAP fee-for-service may not automatically carry over to a managed Medicaid plan. Prescribers should verify coverage under the patient's specific plan before writing the prescription.

If the PA is denied, Delaware Medicaid enrollees have the right to a formal appeal under 42 CFR 431.200, and a clinician-submitted appeal citing abnormal TSH labs on generic therapy has a reasonable chance of approval [5].

Which Commercial Insurance Plans Cover Tirosint in Delaware?

Most commercial insurance plans sold on the Delaware Health Insurance Marketplace (and off-exchange plans from Highmark, Aetna, Cigna, and UnitedHealthcare) place Tirosint on Tier 3 or Tier 4 of their formularies. That translates to copays between $50 and $120 per month after the deductible, depending on plan design.

Horizon BCBS of New Jersey is relevant for southern New Jersey commuters who hold DE employer plans. Employer self-funded plans under ERISA set their own formularies and may or may not include Tirosint; plan documents are the authoritative source.

Medicare Part D does not systematically exclude Tirosint, but most Part D plans in Delaware place it on non-preferred tiers. The CMS Medicare Part D formulary file for plan year 2025 shows the majority of DE-available plans listing levothyroxine sodium capsule (the generic Tirosint equivalent) at a lower tier than the brand [6]. Patients on Medicare should ask their pharmacist to check whether the generic levothyroxine gel capsule (launched after patent expiration) is covered at a lower copay under their specific plan.

For commercial plan members, the IBSA savings card (see below) is the most direct way to reduce the Tier 3 or Tier 4 copay.

How Does the IBSA Savings Card Work in Delaware?

The IBSA Tirosint savings card is a manufacturer copay assistance program available to commercially insured, non-government-plan patients. Delaware residents who are privately insured and not enrolled in Medicare, Medicaid, or any federal- or state-funded program are eligible.

Eligible patients pay as little as $0 per month through the savings card, depending on their insurance plan's coverage tier. The card covers the gap between the insurance copay and the patient's out-of-pocket maximum per fill, up to program limits set by IBSA. Program limits and eligibility criteria are updated annually; the current program terms are posted on IBSA's patient savings portal.

To activate the card: (1) obtain a Tirosint prescription from a licensed Delaware prescriber; (2) enroll online at IBSA's savings card page or by calling the program hotline; (3) present the card alongside the prescription at any participating Delaware pharmacy. Most major chains participate. The card is not accepted at mail-order pharmacies under government-funded plans.

Patients should re-enroll each calendar year. The savings card is not a coupon; it functions as secondary insurance and processes through the pharmacy benefit manager after the primary claim. A 2020 analysis published in JAMA Internal Medicine noted that manufacturer copay assistance cards effectively reduce patient out-of-pocket costs for brand-name drugs but do not reduce overall plan spending [7]. For the individual Delaware patient, the card can make Tirosint affordable at $0, $25 monthly even when the plan's standard copay is $80 or higher.

Is Compounded Levothyroxine Liquid or Gel Cap Legal in Delaware?

Yes. Licensed 503A compounding pharmacies in Delaware may legally compound levothyroxine in liquid or gel-capsule form for individual patients with a valid, patient-specific prescription from a Delaware-licensed prescriber. Compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act is legal when: the compound is prepared for a specific patient based on a licensed prescriber's order; the pharmacy holds a valid Delaware Board of Pharmacy license; and the preparation is not a copy of a commercially available drug without clinical justification [8].

That last point is where compounded levothyroxine sits in a regulatory gray zone. Because Tirosint is commercially available, a 503A pharmacy compounding an essentially identical gel capsule must document that the compounded version is not a "copy" and that there is a clinical reason (such as a specific dose not available commercially, or a documented excipient sensitivity to gelatin itself) for compounding rather than dispensing the brand product. The FDA's 2018 draft guidance on compounding of drugs that are essentially copies of commercially available drugs is the relevant regulatory framework [8].

Practically speaking, Delaware's Office of Controlled Substances and the Delaware Board of Pharmacy have not issued state-specific restrictions beyond federal 503A requirements. Patients who need very low doses (below 13 mcg, the lowest Tirosint commercial strength) or highly customized concentrations of liquid levothyroxine have the clearest clinical justification for a compounded product.

Cost is a major driver of interest in compounded levothyroxine. At licensed Delaware 503A pharmacies, compounded levothyroxine liquid or gel capsule can range from approximately $0 to $40 per month, depending on the pharmacy and whether the patient's insurance covers the compound. That is a substantial difference from the $230 Tirosint cash price. However, compounded preparations are not FDA-approved, do not carry the same bioavailability data as Tirosint, and the American Thyroid Association and the Endocrine Society both caution against routine substitution of compounded thyroid preparations for FDA-approved products without specific clinical indication [4][9].

A 2013 study in Thyroid (Burch et al.) found that variability in levothyroxine tablet potency across manufacturers was a clinically meaningful concern [10]. Compounded preparations introduce an additional layer of variability absent from IBSA's controlled manufacturing process. Prescribers should weigh that tradeoff explicitly with each patient.

HealthRX Clinical Decision Framework: Choosing Between Tirosint and Compounded Levothyroxine in Delaware

| Patient Profile | Recommended Path | Rationale | |---|---|---| | Insured, no malabsorption, stable on generic tablet | Generic levothyroxine tablet | Lowest cost; equivalent efficacy in most patients | | Insured, malabsorption or excipient intolerance | Tirosint + IBSA savings card | FDA-approved; savings card reduces copay; PA may be needed | | Uninsured, malabsorption documented | Tirosint + IBSA savings card or 503A compound | Compare costs; document clinical rationale for compound if chosen | | Delaware Medicaid, PA approved | Tirosint (brand) | Zero copay under Medicaid if PA granted | | Dose below 13 mcg required | 503A compounded liquid | Strongest clinical justification for compounding | | Gelatin allergy (vegetarian/vegan capsule needed) | 503A compound in non-gelatin base | Commercial Tirosint capsule contains gelatin |

Can Delaware Patients Get Tirosint via Telehealth?

Telehealth prescribing of Tirosint is permitted in Delaware. Delaware participates in the Interstate Medical Licensure Compact (IMLC), and Delaware-licensed prescribers can issue a Tirosint prescription to a Delaware patient via a synchronous audio-video telehealth encounter without a prior in-person visit, provided the encounter meets the standard of care for establishing a patient-prescriber relationship [11].

Under the current Delaware telehealth statute (16 Del. C. § 9401 et seq.), prescribers must conduct a clinically appropriate evaluation before prescribing any prescription drug. For Tirosint, that means reviewing TSH and free T4 lab values, thyroid history, and current medication list. Audio-only encounters may suffice under Delaware's pandemic-era telehealth flexibilities, but audio-video remains the standard for new patient relationships.

HealthRX connects Delaware patients with board-certified endocrinologists and internal medicine physicians who can order the necessary labs, evaluate results, and prescribe Tirosint (or a compounded alternative) entirely online. Lab draws can be completed at a nearby Quest Diagnostics or LabCorp location in Wilmington, Dover, or Newark before the telehealth visit. TSH measurement sensitivity has improved significantly; current third-generation TSH assays detect concentrations as low as 0.01 mIU/L, enabling precise dose titration [12].

How Does Tirosint Absorption Compare to Standard Levothyroxine Tablets?

The gel-cap formulation dissolves faster and more completely than compressed tablets in patients with altered gastric pH or motility. Vita et al. (2014) demonstrated this in a crossover study: patients taking levothyroxine gel capsules with espresso coffee showed mean free T4 levels 6.5% higher than those taking standard tablets under the same conditions (P<0.05) [2]. The effect was larger still in patients with Helicobacter pylori-related gastritis, where TSH normalization rates favored the gel capsule by a statistically significant margin.

A separate 2011 study by Ianiro et al. in Thyroid (N=31) found that in patients with chronic atrophic gastritis, switching from levothyroxine tablets to gel capsules reduced the levothyroxine dose required to maintain euthyroidism by a mean of 22 mcg/day [13]. That dose reduction has a direct pharmacoeconomic implication: patients absorbing medication more completely may require fewer total micrograms, partially offsetting the higher unit cost.

The FDA's current levothyroxine guidance notes that absorption can be affected by gastric acidity, concurrent medications (calcium carbonate, ferrous sulfate, cholestyramine, proton pump inhibitors), and food timing [1]. Standard dosing instructions call for taking levothyroxine on an empty stomach, 30 to 60 minutes before breakfast. Gel capsules retain a meaningful absorption advantage over tablets even when this instruction is followed imperfectly, which describes most real-world patients.

Monitoring and Lab Costs in Delaware: The Full Picture

The drug cost is only part of the monthly expense. Delaware patients on Tirosint (or any levothyroxine formulation) require TSH monitoring every 6 to 12 months once stable, per the American Thyroid Association 2014 guideline [4]. A TSH draw at a Delaware LabCorp or Quest site costs approximately $30, $75 cash-pay, or is typically covered under preventive or diagnostic lab benefits by commercial and Medicaid plans.

Patients newly started on Tirosint or switching from tablets should have TSH checked at 6 to 8 weeks after initiation or dose change. The Endocrine Society's clinical practice guideline on hypothyroidism (2012) recommends targeting a TSH of 0.5, 2.5 mIU/L for most adults on levothyroxine replacement, with individualization for age, cardiovascular status, and symptoms [9]. Overtreated hypothyroidism (TSH <0.1 mIU/L) is associated with increased atrial fibrillation risk and bone loss, making accurate dose titration genuinely consequential [14].

Total annual costs for a Delaware patient on Tirosint paying cash include approximately $2 to 760 in drug costs ($230 x 12), plus $60, $150 in lab monitoring, plus prescriber visit costs. For a patient using the IBSA savings card with commercial insurance, the drug cost component may drop to $0, $300 annually.

State-Specific Delaware Pharmacy Resources

Delaware has 44 licensed retail pharmacies per 100,000 population, slightly below the national median of 47 [15]. Pharmacy deserts are a real concern in rural Sussex County. Delaware residents in areas with limited local pharmacy access may use mail-order pharmacies under their commercial plan for 90-day Tirosint supplies, typically at a lower per-dose cost.

Delaware's Prescription Assistance Program (administered through the Delaware Department of Health and Social Services) provides supplemental drug cost assistance for residents earning up to 200% of the federal poverty level who are ineligible for Medicaid. Tirosint is not automatically included, but patients can apply for case-by-case assistance. The DHSS pharmaceutical assistance line is the appropriate contact for eligibility verification.

Delaware also participates in the National Association of Boards of Pharmacy (NABP) verified internet pharmacy practice sites (VIPPS) program, which allows patients to confirm whether an online pharmacy is legitimate before ordering [16]. Canadian or offshore online pharmacies offering "cheap Tirosint" are not subject to FDA oversight and should be avoided.